全部药品（32）

原研: Tagrisso · AstraZeneca

非小细胞肺癌

原研: Xalkori · Pfizer

ALK 阳性非小细胞肺癌

原研: Alecensa · Roche (Genentech in the US; originated by Chugai Pharmaceutical)

ALK 阳性非小细胞肺癌

原研: Gavreto · Discovered by Blueprint Medicines; co-commercialised with Genentech (Roche) in the US and by Roche ex-US; Blueprint regained global rights (excluding Greater China) in 2023

RET 融合肺癌

原研: Tabrecta · Novartis (discovered by Incyte, licensed to Novartis in 2009)

MET14 跳跃突变肺癌

原研: Lumakras · Amgen

KRAS G12C 突变肺癌

原研: Lorbrena · Pfizer Inc.

ALK 阳性晚期肺癌

原研: Avastin · Genentech, Inc. / F. Hoffmann-La Roche Ltd

多种实体瘤

原研: Herceptin · Genentech, Inc. / F. Hoffmann-La Roche Ltd

HER2 阳性乳腺癌 / 胃癌

原研: Ibrance · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc)

HR+/HER2- 晚期乳腺癌

原研: Verzenio · Eli Lilly and Company (Lilly USA, LLC)

HR+/HER2- 晚期乳腺癌

原研: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)

BRCA 突变卵巢癌

原研: Zejula · GlaxoSmithKline (GSK); originally developed by Tesaro (Tesaro UK Limited)

卵巢癌维持治疗

原研: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC

淋巴瘤、慢淋白血病

原研: Rituxan · Genentech, Inc. (a member of the Roche Group), with Biogen; Rituxan is jointly marketed by Biogen and Genentech USA in the US; MabThera is marketed by Roche

淋巴瘤、白血病

原研: Aubagio · Genzyme Corporation, a Sanofi company (US label lists Genzyme Corporation, Cambridge, MA; Sanofi markets Aubagio)

多发性硬化

原研: Humira · AbbVie (originally developed and marketed by Abbott Laboratories; initial U.S. approval 2002)

类风湿关节炎、强直性脊柱炎、银屑病、克罗恩病

原研: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)

类风湿关节炎

原研: Olumiant · Eli Lilly and Company (co-developed with Incyte; initial U.S. approval 2018)

类风湿关节炎

原研: Remicade · Janssen Biotech / Johnson & Johnson (originally Centocor); initial U.S. approval 1998

炎症性肠病、类风湿

原研: Epclusa · Gilead Sciences (Gilead Sciences Ireland UC for the EU)

慢性丙型肝炎

原研: Januvia · Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc.

2 型糖尿病

原研: Galvus · Novartis

2 型糖尿病

原研: Tradjenta · Boehringer Ingelheim (marketed in the US by Boehringer Ingelheim Pharmaceuticals, Inc.; co-promoted with Eli Lilly in several markets)

2 型糖尿病（肾病患者可用）

原研: Forxiga · AstraZeneca (originally developed with Bristol-Myers Squibb)

2 型糖尿病 / 心衰 / 慢性肾病

原研: Jardiance · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)

2 型糖尿病 / 心衰

原研: Invokana · Janssen Pharmaceuticals (Johnson & Johnson), licensed from Mitsubishi Tanabe Pharma

2 型糖尿病

原研: Actos; Actoplus Met and Actoplus Met XR · Takeda Pharmaceutical Company (first US approval 1999)

2 型糖尿病

原研: Victoza · Novo Nordisk

2 型糖尿病 / 减重

原研: Lantus · Sanofi

1 型 / 2 型糖尿病

原研: Tresiba · Novo Nordisk

1 型 / 2 型糖尿病

原研: NovoRapid · Novo Nordisk

1 型 / 2 型糖尿病